Rasilez HCT aliskiren/hydrochlorothiazide regulatory update

Novartis said that in January the EC approved an MAA for Rasilez HCT aliskiren/hydrochlorothiazide to treat hypertension. The fixed-dose combination of a direct renin inhibitor and diuretic, which wa...